These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Demographic and clinical features of hidradenitis suppurativa in Korea. Yang JH; Moon J; Kye YC; Kim KJ; Kim MN; Ro YS; Park MY; Ahn HH; Lee MW; Lee WJ; Lee JH; Lee JB; Jang MS; Choi YS; Choi YW; Suh DH; J Dermatol; 2018 Dec; 45(12):1389-1395. PubMed ID: 30294846 [TBL] [Abstract][Full Text] [Related]
24. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. Gold DA; Reeder VJ; Mahan MG; Hamzavi IH J Am Acad Dermatol; 2014 Apr; 70(4):699-703. PubMed ID: 24433875 [TBL] [Abstract][Full Text] [Related]
26. Questionnaire-based diagnosis of hidradenitis suppurativa: specificity, sensitivity and positive predictive value of specific diagnostic questions. Esmann S; Dufour DN; Jemec GB Br J Dermatol; 2010 Jul; 163(1):102-6. PubMed ID: 20331444 [TBL] [Abstract][Full Text] [Related]
27. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study. Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335 [TBL] [Abstract][Full Text] [Related]
28. Canakinumab for Severe Hidradenitis Suppurativa: Preliminary Experience in 2 Cases. Houriet C; Seyed Jafari SM; Thomi R; Schlapbach C; Borradori L; Yawalkar N; Hunger RE JAMA Dermatol; 2017 Nov; 153(11):1195-1197. PubMed ID: 28854317 [No Abstract] [Full Text] [Related]
29. High prevalence of clinical spondyloarthritis features in patients with hidradenitis suppurativa. Rondags A; van Straalen KR; Arends S; van der Zee HH; Prens EP; Spoorenberg A; Horváth B J Am Acad Dermatol; 2019 Feb; 80(2):551-554.e1. PubMed ID: 30554892 [No Abstract] [Full Text] [Related]
31. Guselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review. Casseres RG; Kahn JS; Her MJ; Rosmarin D J Am Acad Dermatol; 2019 Jul; 81(1):265-267. PubMed ID: 30562567 [No Abstract] [Full Text] [Related]
32. Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients. Weber P; Seyed Jafari SM; Yawalkar N; Hunger RE J Am Acad Dermatol; 2017 Jun; 76(6):1189-1191. PubMed ID: 28522043 [No Abstract] [Full Text] [Related]
33. Long-term efficacy of etanercept in hidradenitis suppurativa: results from an open-label phase II prospective trial. Pelekanou A; Kanni T; Savva A; Mouktaroudi M; Raftogiannis M; Kotsaki A; Giamarellos-Bourboulis EJ Exp Dermatol; 2010 Jun; 19(6):538-40. PubMed ID: 19758320 [TBL] [Abstract][Full Text] [Related]
35. Pharmaceutical Benefits Scheme listing of adalimumab for hidradenitis suppurativa: Is hidradenitis suppurativa a life-changing drug or does lifestyle change the drug? Vekic DA; Frew JW Australas J Dermatol; 2018 Aug; 59(3):e243-e244. PubMed ID: 29285755 [No Abstract] [Full Text] [Related]
36. Interobserver variability of clinical scores in hidradenitis suppurativa is low. Sartorius K; Killasli H; Heilborn J; Jemec GB; Lapins J; Emtestam L Br J Dermatol; 2010 Jun; 162(6):1261-8. PubMed ID: 20184581 [TBL] [Abstract][Full Text] [Related]
37. Hemoglobin as an indicator of disease activity in severe hidradenitis suppurativa. Braunberger TL; Lowes MA; Hamzavi IH Int J Dermatol; 2019 Sep; 58(9):1090-1091. PubMed ID: 30094834 [No Abstract] [Full Text] [Related]
38. Epidemiologic and clinical features of hidradenitis suppurativa. Parulkar I; Haleem H; Paek SY Semin Cutan Med Surg; 2017 Jun; 36(2):42-46. PubMed ID: 28538742 [TBL] [Abstract][Full Text] [Related]
39. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab. Harde V; Mrowietz U J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236 [TBL] [Abstract][Full Text] [Related]